Jeffery M Weinberg

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi request reprint Topical therapy for actinic keratoses: current and evolving therapies
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
    Rev Recent Clin Trials 1:53-60. 2006
  2. ncbi request reprint Nodular fasciitis: a possible side effect of etanercept?
    Kathleen Vine
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Ste 11D, New York, NY 10025, USA
    Cutis 92:199-202. 2013
  3. ncbi request reprint Acquired dermal melanocytosis
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
    Am J Clin Dermatol 8:59-60. 2007
  4. ncbi request reprint The utility of benzoyl peroxide in hydrophase base (Brevoxyl) in the treatment of acne vulgaris
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
    J Drugs Dermatol 5:344-9. 2006
  5. ncbi request reprint Formulary review of therapeutic alternatives for atopic dermatitis: focus on pimecrolimus
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
    J Manag Care Pharm 11:56-64. 2005
  6. ncbi request reprint Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA
    J Drugs Dermatol 1:303-10. 2002
  7. ncbi request reprint Atopic dermatitis: a new treatment paradigm using pimecrolimus
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA
    J Drugs Dermatol 2:131-40. 2003
  8. ncbi request reprint Cutaneous infections in the elderly: diagnosis and management
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
    Dermatol Ther 16:195-205. 2003
  9. ncbi request reprint Skin infections in the elderly
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
    Dermatol Clin 22:51-61. 2004
  10. ncbi request reprint Successful treatment of recalcitrant palmoplantar psoriasis with etanercept
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
    Cutis 72:396-8. 2003

Collaborators

Detail Information

Publications78

  1. ncbi request reprint Topical therapy for actinic keratoses: current and evolving therapies
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
    Rev Recent Clin Trials 1:53-60. 2006
    ..Several topical treatment options have been shown to offer some significant benefit in the alleviation of these lesions. The therapies include 5-fluorouracil, imiquimod, diclofenac, colchicine and retinoids...
  2. ncbi request reprint Nodular fasciitis: a possible side effect of etanercept?
    Kathleen Vine
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Ste 11D, New York, NY 10025, USA
    Cutis 92:199-202. 2013
    ..We report a case of biopsy-proven nodular fasciitis (NF) that developed in an otherwise healthy man with plaque psoriasis who was undergoing treatment with etanercept. ..
  3. ncbi request reprint Acquired dermal melanocytosis
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
    Am J Clin Dermatol 8:59-60. 2007
  4. ncbi request reprint The utility of benzoyl peroxide in hydrophase base (Brevoxyl) in the treatment of acne vulgaris
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
    J Drugs Dermatol 5:344-9. 2006
    ..Clinical studies demonstrating the efficacy and safety of benzoyl peroxide in hydrophase base will be reviewed...
  5. ncbi request reprint Formulary review of therapeutic alternatives for atopic dermatitis: focus on pimecrolimus
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
    J Manag Care Pharm 11:56-64. 2005
    ..Pimecrolimus is indicated for mild-to-moderate AD. The objective of this article is to review the key characteristics that differentiate pimecrolimus from steroids and tacrolimus in the treatment of AD...
  6. ncbi request reprint Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA
    J Drugs Dermatol 1:303-10. 2002
    ..The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data...
  7. ncbi request reprint Atopic dermatitis: a new treatment paradigm using pimecrolimus
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA
    J Drugs Dermatol 2:131-40. 2003
    ..We then discuss various aspects of pimecrolimus, including pharmacologic properties, toxicology, short- and long-term studies, and safety and adverse events. Finally, we propose a new steroid-sparing treatment strategy for AD...
  8. ncbi request reprint Cutaneous infections in the elderly: diagnosis and management
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
    Dermatol Ther 16:195-205. 2003
    ..With limited treatment options, it has become critical to identify antibiotics with novel mechanisms of activity. Several new drugs have emerged as possible therapeutic alternatives, including linezolid and quinupristin/dalfopristin...
  9. ncbi request reprint Skin infections in the elderly
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
    Dermatol Clin 22:51-61. 2004
    ..With treatment options limited, it has become critical to identify antibiotics with novel mechanisms of activity. Several new drugs have emerged as possible therapeutic alternatives, including linezolid and quinupristin-dalfopristin...
  10. ncbi request reprint Successful treatment of recalcitrant palmoplantar psoriasis with etanercept
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
    Cutis 72:396-8. 2003
    ..We report a case of successful treatment of recalcitrant palmoplantar psoriasis with etanercept in a 59-year-old woman unresponsive to other treatment modalities...
  11. ncbi request reprint An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
    Clin Ther 25:2487-505. 2003
    ..One of the major focuses in psoriasis research has been the development of biologic therapies that provide selective, immunologically directed intervention with fewer adverse effects than traditional therapies...
  12. ncbi request reprint Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept
    Jeffrey M Weinberg
    Department of Dermatology St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
    Cutis 71:41-5. 2003
    ..The first article of this 2-part update reviewed the tumor necrosis factor (TNF) inhibitors, infliximab and etanercept. In this article, we will review 2 therapies that target the T cell, efalizumab and alefacept...
  13. ncbi request reprint Herpes zoster: epidemiology, natural history, and common complications
    Jeffrey M Weinberg
    Clinical Research Center, Department of Dermatology, St Luke s Roosevelt Hospital Center, and Columbia University College of Physicians and Surgeons, New York, New York 10025, USA
    J Am Acad Dermatol 57:S130-5. 2007
    ..The zoster vaccine may help prevent the onset of herpes zoster in the target population of those age 60 years and older. This summary reviews the epidemiology, pathogenesis, natural history, and common symptoms of zoster disease...
  14. ncbi request reprint Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept
    William D Tutrone
    St Luke s Roosevelt Hospital Center, Department of Dermatology, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
    IDrugs 7:45-9. 2004
    ....
  15. ncbi request reprint Treatment of interdigital tinea pedis: once-daily therapy with sertaconazole nitrate
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY, USA
    J Drugs Dermatol 10:1135-40. 2011
    ..8 percent were free of pruritus; no relapses had occurred. These encouraging findings suggest that sertaconazole nitrate may be useful in a once-daily regimen and also may result in better patient adherence to therapy...
  16. ncbi request reprint Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus
    Jeffrey M Weinberg
    Clinical Research Center, Department of Dermatology, St Luke s Roosevelt Hospital Center, NewYork, NY 10025, USA
    J Drugs Dermatol 9:1198-204. 2010
    ..aureus and Streptococcus pyogenes and may play an important role in limiting the development of resistance against systemic agents...
  17. ncbi request reprint Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
    J Drugs Dermatol 4:544-55. 2005
    ....
  18. ncbi request reprint Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
    Cutis 71:25-9. 2003
    ..The structure and mechanism of each drug will be reviewed, as well as the most recent clinical experience and safety data. The first article of this review will focus on the therapies that inhibit tumor necrosis factor alpha (TNF-alpha)...
  19. ncbi request reprint Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept
    Boback Berookhim
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
    Cutis 74:245-7. 2004
    ..To our knowledge, this is the first report of its efficacy in the treatment of PV...
  20. ncbi request reprint Etanercept
    Erin Ducharme
    St Luke s Roosevelt Hospital Center, Department of Dermatology, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
    Expert Opin Biol Ther 8:491-502. 2008
    ..Etanercept is a soluble fusion protein that binds TNF-alpha, rendering the molecule inactive and making etanercept an effective, targeted therapeutic option for many TNF-mediated inflammatory diseases...
  21. ncbi request reprint Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus
    Ritu Saini
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, 1090 Amsterdam Avenue, New York, NY 10025, USA
    Curr Pharm Des 11:273-80. 2005
    ..Clinical data for these agents, including the most recent phase II and/or III study results, will be discussed, as well as the most recent safety data...
  22. ncbi request reprint Topical therapy in the treatment of actinic keratosis and basal cell carcinoma
    Marissa D Newman
    Department of Dermatology, UMDNJ Robert Wood Johnson Medical School, Newark, USA
    Cutis 79:18-28. 2007
    ..The topical therapies include 5-fluorouracil (5-FU), diclofenac sodium, colchicine, retinoids, and imiquimod. Topical treatment of basal cell carcinoma (BCC) with imiquimod also will be discussed...
  23. ncbi request reprint Levamisole in dermatology : a review
    Noah Scheinfeld
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Centers, New York, New York 10025, USA
    Am J Clin Dermatol 5:97-104. 2004
    ..It can rarely cause agranulocytosis. More studies need to be undertaken to study the full potential of levamisole in dermatologic diseases...
  24. ncbi request reprint Innovative uses of tumor necrosis factor alpha inhibitors
    Joni Mazza
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY, USA
    Dermatol Clin 28:559-75. 2010
    ..Numerous case reports and case series have been published in recent years reporting the off-label uses of these drugs in various inflammatory skin diseases. This review summarizes the most recent reports on 20 such conditions...
  25. ncbi request reprint The preauricular sinus: a review of its clinical presentation, treatment, and associations
    Noah S Scheinfeld
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York, USA
    Pediatr Dermatol 21:191-6. 2004
    ..Recurrence rates after surgery range from 9% to 42%. Meticulous excision by an experienced head and neck surgeon minimizes the risk of recurrence...
  26. ncbi request reprint Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin
    Eric S Schweiger
    Department of Dermatology, St Luke s Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA
    J Drugs Dermatol 2:378-83. 2003
    ..Several new drugs have emerged as possible therapeutic alternatives. This review focuses on agents newly introduced and FDA-approved for the treatment of skin and skin structure infections: linezolid and quinupristin/dalfopristin...
  27. doi request reprint Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus
    Maryann Mikhail
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Ste 11B, New York, NY 10025, USA
    Arch Dermatol 144:453-6. 2008
  28. ncbi request reprint Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents
    Jeffrey M Sobell
    Tufts Medical Center, Department of Dermatology, Boston, MA 02111, USA
    J Drugs Dermatol 8:230-8. 2009
    ..One of these new agents is ustekinumab, a humanized antibody that targets interleukins 12 and 23 and inhibits the differentiation of Th17 cells, a recently identified subset of CD4+ T-helper cells...
  29. ncbi request reprint Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 3: Clinical management
    Erin H Kil
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
    Cutis 81:327-35. 2008
    ..This 4-part review covers the epidemiology, pathogenesis, and management of the disease, including new treatment options. The third part of the review will focus on the clinical management of MRSA infection...
  30. ncbi request reprint Therapeutic options for herpes labialis, I: Oral agents
    Diana Elish
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
    Cutis 74:31-4. 2004
    ..In this series of articles, we review oral and topical therapeutic agents that are available in the treatment of herpes labialis and its associated symptoms. This article will review oral treatment options...
  31. ncbi request reprint Novel antibacterial agents for skin and skin structure infections
    Eric S Schweiger
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Avenue, New York, NY 10025, USA
    J Am Acad Dermatol 50:331-40; quiz 341-2. 2004
    ....
  32. ncbi request reprint Famciclovir for cutaneous herpesvirus infections: an update and review of new single-day dosing indications
    Manju Chacko
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, New York, NY 10025, USA
    Cutis 80:77-81. 2007
    ..Famciclovir has received single-day dosing indications for both of these entities. The studies leading to these new indications are reviewed...
  33. ncbi request reprint Efalizumab
    Manju Chacko
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York 10025, USA
    Dermatol Ther 20:265-9. 2007
    ..In addition, several off-label applications of efalizumab will be reviewed...
  34. ncbi request reprint Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literature
    Molly M Drehs
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York 10025, USA
    Dermatol Surg 28:427-9. 2002
    ..The use of imiquimod 5% cream for the treatment of superficial basal cell carcinoma (BCC) has been described. Its clinical efficacy was first shown in a study in patients with biopsy-proven superficial and nodular BCC...
  35. ncbi request reprint Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology
    Karen M Wesson
    Department of Dermatology, St Luke s Roosevelt Center, New York, New York 10025, USA
    Clin Dermatol 21:64-70. 2003
  36. ncbi request reprint Viral skin infections in the elderly: diagnosis and management
    Rashmi Bansal
    Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Avenue, New York, NY 10025, USA
    Drugs Aging 19:503-14. 2002
    ..Immunocompromised patients often do not respond to the usual destructive therapies, and intravenous or topical cidofovir may be useful in these patients...
  37. ncbi request reprint Cutaneous HSV-2 infection with serial recurrences at multiple sites
    Anne Dacko
    Department of Dermatology, St Luke s Roosevelt Beth Israel Medical Center, New York, NY 10025, USA
    Int J Dermatol 41:109-11. 2002
  38. ncbi request reprint Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphoma
    Fiza Singh
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
    Cutis 76:186-8. 2005
    ....
  39. ncbi request reprint Medical backgrounder: psoriasis
    Lisa Travis
    Department of Dermatology, St Luke s Roosevelt and Beth Israel Medical Centers, New York, NY, U S A
    Drugs Today (Barc) 38:847-65. 2002
    ..New psoriasis treatment regimens have been developed and include combination, rotational and sequential therapy...
  40. ncbi request reprint Utility of histopathologic analysis in the evaluation of onychomycosis
    Jeffrey M Weinberg
    Clinical Research Center, Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
    J Am Podiatr Med Assoc 95:258-63. 2005
    ..We propose that histopathologic examination is indicated if the results of other methods are negative and clinical suspicion is high; therefore, it is a useful complementary technique in the diagnosis of onychomycosis...
  41. ncbi request reprint Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumab
    Jeffrey M Weinberg
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY, USA
    Arch Dermatol 142:555-8. 2006
  42. ncbi request reprint Cutaneous anthrax: a concise review
    William D Tutrone
    Department of Dermatology, St Luke s Roosevelt Medical Center, New York, New York 10025, USA
    Cutis 69:27-33. 2002
    ....
  43. ncbi request reprint Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 4: Additional therapeutic considerations
    Erin H Kil
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
    Cutis 81:343-7. 2008
    ..The fourth part of the review will focus on additional therapeutic considerations in the management of MRSA infection...
  44. ncbi request reprint Comparison of diagnostic methods in the evaluation of onychomycosis
    Jeffrey M Weinberg
    Department of Dermatology at St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
    J Am Acad Dermatol 49:193-7. 2003
    ..Recent reports have suggested that nail plate biopsy using periodic acid-Schiff (PAS) (Bx/PAS) stain may be a very sensitive technique for the diagnosis of onychomycosis...
  45. ncbi request reprint Oral tazarotene and oral pimecrolimus: novel oral therapies in development for psoriasis
    Fiza Singh
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York 10025, USA
    J Drugs Dermatol 3:141-3. 2004
    ..The goal of this article is to review oral tazarotene, a novel retinoid, and oral pimecrolimus, a novel macrolactam therapy, for the treatment of moderate to severe psoriasis...
  46. ncbi request reprint AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis
    Rachel Nazarian
    St Lukes Roosevelt Hospital Center, Department of Dermatology, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
    Curr Opin Investig Drugs 10:1236-42. 2009
    ..AN-2728 appears to have good therapeutic potential, although further and larger trials are required to assess the long-term safety and characterize the broad utility of this drug...
  47. ncbi request reprint A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia
    Katherine Holcomb
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
    J Drugs Dermatol 5:863-6. 2006
    ..5% (P < .001), and reduced the incidence of herpes zoster by 51.3% (P < .001). In this review, we will discuss the history of the use of the varicella vaccine in children, and the subsequent development of the new zoster vaccine...
  48. ncbi request reprint Study of clinically suspected onychomycosis in a podiatric population
    Maureen B Jennings
    New York College of Podiatric Medicine, 1800 Park Ave, New York, NY 10035, USA
    J Am Podiatr Med Assoc 92:327-30. 2002
    ..The most remarkable risk factor was age, with 80% of affected individuals older than 35 years. False-negatives may account for the high percentage (44%) of negative cultures in this study...
  49. ncbi request reprint Successful treatment of vitiligo with 0.1% tacrolimus ointment
    Lisa B Travis
    St Luke s Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
    Arch Dermatol 139:571-4; discussion 573. 2003
  50. ncbi request reprint Topical antimicrobial agents in dermatology
    Candace Thornton Spann
    Department of Dermatology, St Luke s Roosevelt Center, New York, New York 10025, USA
    Clin Dermatol 21:70-7. 2003
  51. ncbi request reprint Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agents
    Jeffrey M Sobell
    Tufts Medical Center, Department of Dermatology, Boston, Massachusetts SkinCare Physicians, Chestnut Hill, MA 02111, USA
    J Drugs Dermatol 8:147-54. 2009
    ..Part 2 will present new data on T-cell modulators, new molecules in development, and considerations for optimal therapeutic selection for treatment of patients with psoriasis (Journal of Drugs in Dermatology, March 2009)...
  52. ncbi request reprint Macrolides in dermatology
    Noah S Scheinfeld
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York 10025, USA
    Clin Dermatol 21:40-9. 2003
  53. ncbi request reprint Monodermatomal herpes zoster in a pseudodisseminated distribution following breast reconstruction surgery
    Micole Tuchman
    New York Medical College, New York, USA
    Cutis 81:71-2. 2008
    ....
  54. ncbi request reprint Lichen planus in the lines of Blaschko
    Christina Kabbash
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York 10025, USA
    Pediatr Dermatol 19:541-5. 2002
    ..Based on the clinical findings in our patients and a review of the English-language literature, we believe that linear LP is usually distributed along the lines of Blaschko and should be renamed lichen planus, Blaschko subtype...
  55. ncbi request reprint Therapeutic options for herpes labialis, II: Topical agents
    Diana Elish
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
    Cutis 74:35-40. 2004
  56. ncbi request reprint Neurocutaneous disorders
    Joseph S Barbagallo
    Department of Dermatology, St Luke s Roosevelt and Beth Israel Medical Centers, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
    Dermatol Clin 20:547-60, viii. 2002
    ..Many of these diseases are single gene disorders, for which the genes have been discovered in the past few years. The article is divided into sections, highlighting disorders transmitted by different inheritance pattern...
  57. ncbi request reprint Neonatal pemphigus foliaceus
    Ranella Hirsch
    Department of Dermatology, State University of New York Health Science Center at Brooklyn, Brooklyn, NY, USA
    J Am Acad Dermatol 49:S187-9. 2003
    ..The proposed mechanism of disease transfer is the passive transfer of maternal IgG antibodies across the placenta...
  58. ncbi request reprint Idiopathic eruptive macular pigmentation: a case of 21 years' duration
    Sheetal Mehta
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
    J Am Acad Dermatol 49:S280-2. 2003
    ..An unusual case of a 24-year-old woman with idiopathic eruptive macular pigmentation lasting 21 years was characterized by several periods of spontaneous resolution followed by recurrences...
  59. ncbi request reprint Topical antibacterial agents for wound care: a primer
    Candace Thornton Spann
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
    Dermatol Surg 29:620-6. 2003
    ..The ideal topical antibiotic has a broad spectrum of activity, has persistent antibacterial effects, and has minimal toxicity or incidence of allergy...
  60. ncbi request reprint The anti-inflammatory effects of tetracyclines
    Jeffrey M Weinberg
    Clinical Research Center, Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
    Cutis 75:6-11. 2005
    ..In addition, the use of subantimicrobial dose doxycycline 20 mg twice a day (SDD) will be discussed because of its anti-inflammatory effects...
  61. ncbi request reprint Atypical cellular neurothekeoma
    Sonal Bhatia
    Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
    Dermatol Surg 29:1154-7. 2003
    ....
  62. ncbi request reprint Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 1: Epidemiology
    Erin H Kil
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
    Cutis 81:227-33. 2008
    ..This 4-part review covers the epidemiology, pathogenesis, and management of the disease, including new treatment options. The first part of the review will focus on the epidemiology of MRSA infection...
  63. ncbi request reprint Phototherapy of atopic dermatitis
    Noah S Scheinfeld
    Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York 10025, USA
    Clin Dermatol 21:241-8. 2003
  64. ncbi request reprint Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 2: Pathogenesis and cutaneous manifestations
    Erin H Kil
    Department of Dermatology, St Lukes Roosevelt Hospital Center, New York, New York, USA
    Cutis 81:247-54. 2008
    ..This 4-part review covers the epidemiology, pathogenesis, and management of the disease, including new treatment options. The second part of the review will focus on the pathogenesis and cutaneous manifestations of MRSA infection...
  65. ncbi request reprint Topical imiquimod 5% cream in the treatment of Bowen's disease of the penis
    Fran Cook-Bolden
    J Am Acad Dermatol 46:146-7. 2002
  66. ncbi request reprint Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology
    Karen M Wesson
    Dis Mon 50:395-406. 2004
  67. ncbi request reprint Unique approaches for the topical treatment and prevention of cutaneous infections: report from a clinical roundtable
    Lawrence F Eichenfield
    Division of Dermatology, University of California, San Diego School of Medicine, USA
    Cutis 74:2-23. 2004
  68. ncbi request reprint Novel biologic therapies
    Jeffrey M Weinberg
    Rev Recent Clin Trials 1:183. 2006
  69. ncbi request reprint Barriers to biologics
    Jeffrey M Weinberg
    Cutis 74:164. 2004
  70. ncbi request reprint Learning curve
    Jeffrey M Weinberg
    Cutis 72:349. 2003
  71. ncbi request reprint Successful treatment of vulvar intraepithelial neoplasia with topical imiquimod 5% cream in a lung transplanted patient
    Lisa B Travis
    Acta Derm Venereol 82:475-6. 2002
  72. ncbi request reprint Topical therapy for actinic keratoses, II: Diclofenac, colchicine, and retinoids
    William D Tutrone
    University of Vermont, Burlington, USA
    Cutis 71:373-9. 2003
    ..This article is the second in a 2-part series of current topical therapeutic options for AKs and discusses topical diclofenac, colchicine, and retinoids. The first part focused on topical 5-fluorouracil and imiquimod...
  73. ncbi request reprint Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimod
    William D Tutrone
    University of Vermont, Burlington, USA
    Cutis 71:365-70. 2003
    ..Therapies include 5-fluorouracil, imiquimod, diclofenac, colchicine, and retinoids. The first part of this review will focus on topical 5-fluorouracil and imiquimod...
  74. ncbi request reprint Nature of the beast
    Jeffrey M Weinberg
    Cutis 71:343. 2003
  75. ncbi request reprint Pimple positives
    Jeffrey M Weinberg
    Cutis 76:96. 2005
  76. ncbi request reprint Perspectives on psoriasis
    Jeffrey M Weinberg
    Cutis 76:171. 2005
  77. ncbi request reprint Psoriasis in the patient with human immunodeficiency virus, part 1: review of pathogenesis
    Rita V Patel
    University of Miami School of Medicine, Florida, USA
    Cutis 82:117-22. 2008
    ..The first part of the series focuses on the pathogenesis of HIV-associated psoriasis...
  78. ncbi request reprint UV dependence
    Jeffrey M Weinberg
    Cutis 78:25-6. 2006